Excelimmune, Inc., a Woburn, MA-based biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans, received a $1m investment as part of an open Series-B financing round.
The investment comes from a mixture of existing and new investors.
Proceeds from the financing will be used to continue studies of the company’s first drug candidate, Staphguard, a human recombinant polyclonal antibody (HRPA) against methicillin-resistant Staphylococcus aureus (MRSA), a potentially fatal bacterial infection that is commonly acquired in a hospital or other healthcare setting.
Excelimmune has successfully completed a pre-clinical mouse study of Staphguard and in order to advance its development towards an IND filing, the company is partnering with Clinquest, a Healthcare Product Development Service Organization.
In September 2009, Excelimmune was awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Institutes of Health (NIH) to develop a HRPA against Clostridium difficile.